Recent Updates
Recently added Catalysts

Evogene Ltd.

EVGNFDA catalysts, PDUFA dates & pipeline intelligence
$0.32
▲ +0 · +1.02%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full EVGN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2552W HIGH $1.26
Volume
62.77 K
Value Traded
19.14 K
Short % Float
0.62%
Days to Cover
2.3
-14.77%Week
-14.63%1 Month
-43.79%3 Month
-54.83%6 Month
-70.72%1 Year
-98.43%5 Year
-94.81%All Time

Cash Data

Unlock EVGN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.30 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
13.59 M
Float Shares
11.38 M
Insiders
36.98%
Institutions
2.87%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every EVGN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

EVGN Catalyst Timeline

Dated clinical, regulatory and corporate events for Evogene Ltd.

Unlock the full EVGN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How EVGN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all EVGN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Unlock the EVGN pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every EVGN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
BMC128 advanced solid tumorsPhase 12026-06-02total patients: 11; stable disease patients: 5; partial response patients: 1; patients on study: 2Read MoreEvogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary BiomicaRead More
Scroll for more · summaries link to the source press release
Unlock every EVGN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock EVGN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
RECANATI LEONDirectorBuy 460,000 1,343,886 held$0.64 08/11/2026
Unlock the full EVGN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SILVERARC CAPITAL MANAGEMENT, LLC 0.2 % (-60 %) 945.48 K 307.97 K -90% ( -2.77 M)
Unlock every fund holding EVGN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in EVGN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see EVGN ownership
Insider and institutional ownership, quarter by quarter.

EVGN Short Interest

Shares sold short, counted twice a month.

0.62%
Short % of Float
of tradable shares sold short
70.3K
Shares Sold Short
+10.1% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
30.1K
Avg Daily Volume
the average used for days to cover
Unlock EVGN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock EVGN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live EVGN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock EVGN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How EVGN ranks across every disease it competes in

Competitive Position is a premium feature
See how EVGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

EVGN News

EVGN
Nov 19, 2026
EVGNGeneral
▼ -10.6%on this news

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

Evogene Ltd. reported its Q3 and nine-month financial results for 2026, highlighting progress in its drug discovery program targeting acute graft-versus-host disease and AgPlenus' fungicide initiatives. The company generated novel small-molecule candidates with biological potency and promising activity against resistant fungal strains. Despite a decrease in revenues, Evogene continues to focus on building a proprietary asset pipeline.

Read more →
EVGN
Nov 5, 2026
EVGNConferences/Events
▼ -7.6%on this news· ran to -24% by day 1

Evogene Schedules Third Quarter 2026 Financial Results Release

Evogene Ltd. will release its financial results for Q3 2026 on November 19, 2026. A conference call will follow at 9:00 AM ET to discuss these results. The company specializes in computational chemistry and generative design for pharmaceuticals and agriculture, leveraging its proprietary AI technology.

Read more →
EVGN
Oct 28, 2026
EVGNGeneral

Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program

Evogene Ltd. announced acute graft-versus-host disease (aGVHD) as the target for its AI-driven drug discovery program. The initiative aims to develop a first-in-class small-molecule therapeutic for steroid-refractory patients. With a significant market opportunity, the program has already generated novel candidates demonstrating high potency and favorable profiles. The project is supported by leading experts in the field.

Read more →
EVGN
Oct 26, 2026
EVGNConferences/Events

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene Ltd. will participate in BIO-Europe and Drug Discovery Chemistry Europe in November 2026. Dr. Gabi Tarcic will represent the company at BIO-Europe for potential partnerships. At Drug Discovery Chemistry Europe, Evogene will present a poster on its ChemPass AI™ platform, aimed at enhancing drug discovery processes.

Read more →
EVGN
Oct 20, 2026
EVGNConferences/Events

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene Ltd. announced its participation in the AI Drug Discovery Roadshow from November 2-5, 2026, across the U.S. East Coast. The event, organized by the Israel Export Institute and TradeIL, aims to connect Israeli biotech firms with U.S. investors and pharmaceutical companies. CEO Ofer Haviv will present their ChemPass AI™ platform, designed for optimizing small molecules in drug development.

Read more →
EVGN
Oct 6, 2026
EVGNGeneral

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene Ltd. has entered a cooperation agreement with Pure Capital Group to resolve disputes and reconstitute its Board of Directors. This agreement aims to provide operational stability and allows Evogene to concentrate on its AI-driven small-molecule discovery efforts. The deal includes the replacement of two board members and a commitment to avoid legal disputes.

Read more →
EVGN
Sep 30, 2026
EVGNFDA Updates

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Ltd. has received a letter from Nasdaq granting an additional 180 days to meet the minimum bid price compliance requirement. The company must ensure its share price reaches at least $1.00 for ten consecutive business days by March 29, 2027, to avoid delisting. Evogene is focused on regaining compliance and may consider a reverse share split if necessary.

Read more →
EVGN
Aug 31, 2026
EVGNGeneral

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene Ltd. has responded to dissident shareholders urging a board overhaul, emphasizing the significant changes made in the past 18 months. The company highlights its successful partnerships, reduced cash burn, and new board members with relevant expertise. Evogene encourages shareholders to support its nominees at the upcoming Annual General Meeting.

Read more →
EVGN
Aug 25, 2026
EVGNGeneral

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Ltd. has received recommendations from leading proxy advisory firms ISS and Glass Lewis to support its slate of director nominees at the upcoming Annual General Meeting. The firms highlighted the board's recent turnover and the relevant experience of the management nominees. The board urges shareholders to disregard the dissident nominees, emphasizing the importance of maintaining strategic momentum.

Read more →
EVGN
Aug 18, 2026
EVGNGeneral

Evogene Reports Second Quarter and First Half 2026 Financial Results

Evogene Ltd. reported its financial results for the second quarter and first half of 2026, highlighting a strategic transformation into an AI-driven computational chemistry company. The company has reduced its workforce and operating expenses while establishing six active drug development collaborations. Despite a decrease in revenues, Evogene anticipates a significant reduction in cash burn and has expanded its virtual chemical space significantly.

Read more →
EVGN
Aug 14, 2026
EVGNGeneral
▼ -7.7%on this newsshared move

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Ltd. will have Chairman Nir Nimrodi participate in a quarterly results call on August 18, 2026, to discuss the situation with dissident shareholders. He will provide insights into the company's perspective and the implications of these developments. The call aims to address shareholder concerns and ensure transparency regarding the company's operations.

Read more →
EVGN
Jul 30, 2026
EVGNConferences/Events

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene Ltd. has announced the release of its financial results for the second quarter of 2026, scheduled for August 18, 2026. Following the release, a conference call will be held at 9:00 AM ET to discuss the results. The company specializes in the generative design of small molecules, aiming to innovate in the pharmaceutical and agricultural sectors.

Read more →
EVGN
Jun 24, 2026
EVGNGeneral
▼ -10.5%on this news

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Evogene Ltd. has achieved a significant milestone in its collaboration with Google Cloud, enhancing its ChemPass AI™ platform for small-molecule discovery. This integration aims to streamline the identification of key success criteria early in the development process, potentially increasing the likelihood of success and reducing discovery timelines. The collaboration leverages advanced AI technologies to redefine molecular discovery in the pharmaceutical sector.

Read more →
EVGN
Jun 9, 2026
EVGNConferences/Events

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceut

Read more →
EVGN
Jun 2, 2026
EVGNPhases
▼ -13.6%on this news

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Ltd. announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product, in combination with Nivolumab for patients with advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signs of clinical activity, with several patients achieving stable disease. The findings support the continued development of BMC128 by Lishan Biotech.

Read more →
EVGN
May 20, 2026
EVGNGeneral

Evogene Reports First Quarter 2026 Financial Results

Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical

Read more →
EVGN
May 12, 2026
EVGNConferences/Events

Evogene to Present at the 24th Schrödinger European User Group Meeting

Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical

Read more →
EVGN
May 7, 2026
EVGNGeneral

Evogene Schedules First Quarter 2026 Financial Results Release

Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and

Read more →
EVGN
Apr 2, 2026
EVGNFDA Updates

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Evogene Ltd. received a notification from Nasdaq regarding non-compliance with the minimum bid price rule, as its shares have been below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance, with options including a potential reverse stock split. Failure to comply may result in delisting from Nasdaq, although trading will continue during this period.

Read more →
EVGN
Mar 9, 2026
EVGNConferences/Events

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Ltd. will present its latest pharmaceutical discoveries at the BIO-Europe Spring 2026 conference in Lisbon. Key presentations will focus on the company's advancements in AI-driven small-molecule discovery, particularly through its ChemPass AI™ technology. Attendees will have the opportunity to meet with Evogene's executives for further discussions on collaborative drug discovery.

Read more →

About Evogene Ltd.

52 employees evogene.com
HeadquartersRehovot
Founded1999
BIOPHARMAWATCH ELITE
Trade the next EVGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime